CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.87
+0.67%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.87
From 52W high−72.93%
Volume289221.00
Market cap$67.60M
P/E (TTM)—
P/S (TTM)133.1x
Div yield—
Key dataNov 4, 2026
Open
$0.87
From 52W high
−72.93%
Volume
289221.00
Market cap
$67.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
38.9
MomentumView details →
1D Return
+0.67%
YTD Return
−69.00%
SummaryUpdated Jun 1, 2026
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a clinical-stage biotechnology company founded in 1999 and headquartered in San Diego, California. Originally incorporated as Trovagene, Inc., the company changed its name to Cardiff Oncology in May 2012 to reflect its focused mission on developing innovative cancer treatments. The company went public in 2004 and has since dedicated itself to advancing novel therapeutic approaches for cancer patients, with a particular emphasis on targeting specific molecular pathways that drive tumor growth and resistance to existing treatments.
Similar companies
Latest newsMore news →
Cardiff Oncology said Chief Medical Officer Roger Sidhu departed by mutual agreement effective October 22, 2026, and Leila Alland was appointed interim Chief Medical Officer effective October 23, 2026.8d agoThe U.S. Food and Drug Administration granted orphan drug designation to Cardiff Oncology, Inc.’s onvansertib for treating chronic myelomonocytic leukemia.14d ago